المؤلفون: Kenna JG; Safer Medicines Trust, Kingsbridge, UK., Taskar KS; Mechanistic Safety and Disposition, IVIVT, GlaxoSmithKline, Ware, Hertfordshire, UK., Battista C; DILIsym Services Inc., a Simulations Plus Company, Research Triangle Park, North Carolina, USA., Bourdet DL; Drug Metabolism and Pharmacokinetics, Theravance Biopharma, South San Francisco, California, USA., Brouwer KLR; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Brouwer KR; ADME-TOX, BioIVT, Durham, North Carolina, USA., Dai D; Clinical Pharmacology, Research and Development Sciences, Agios Pharmaceuticals, Cambridge, Massachusetts, USA., Funk C; Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Hafey MJ; Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Merck & Co., Inc, Kenilworth, New Jersey, USA., Lai Y; Drug Metabolism, Gilead Sciences Inc., Foster City, California, USA., Maher J; Safety Assessment, Genentech, South San Francisco, California, USA., Pak YA; Lilly Research Laboratory, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA., Pedersen JM; Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Novum, Huddinge, Sweden., Polli JW; Mechanistic Safety and Drug Disposition, GlaxoSmithKline, King of Prussia, Pennsylvania, USA., Rodrigues AD; PDM, Medicine Design, Pfizer Inc., Groton, Connecticut, USA., Watkins PB; Institute for Drug Safety Sciences, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA., Yang K; DILIsym Services Inc., a Simulations Plus Company, Research Triangle Park, North Carolina, USA., Yucha RW; Takeda Pharmaceuticals, Global Drug Metabolism and Pharmacokinetics, Cambridge, Massachusetts, USA.

مؤلفون مشاركون: International Transporter Consortium

المصدر: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2018 Nov; Vol. 104 (5), pp. 916-932.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Review

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE

مواضيع طبية MeSH: ATP Binding Cassette Transporter, Subfamily B, Member 11/*antagonists & inhibitors , Bile/*metabolism , Chemical and Drug Induced Liver Injury/*etiology , Drug Development/*methods , Drug Discovery/*methods , Liver/*drug effects , Membrane Transport Modulators/*toxicity, ATP Binding Cassette Transporter, Subfamily B, Member 11/chemistry ; ATP Binding Cassette Transporter, Subfamily B, Member 11/genetics ; ATP Binding Cassette Transporter, Subfamily B, Member 11/metabolism ; Animals ; Cells, Cultured ; Chemical and Drug Induced Liver Injury/genetics ; Chemical and Drug Induced Liver Injury/metabolism ; Chemical and Drug Induced Liver Injury/prevention & control ; Computer Simulation ; Computer-Aided Design ; Drug Design ; Humans ; In Vitro Techniques ; Liver/metabolism ; Membrane Transport Modulators/chemistry ; Models, Biological ; Protein Conformation ; Risk Assessment ; Risk Factors ; Structure-Activity Relationship